[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"preeclampsia-severe\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:preeclampsia-severe":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,47],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":29,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100629698","phase-4-biomarkers-in-management-of-post-partum-preeclampsia-100629698",false,"NCT07478055","Biomarkers in Management of Post Partum Preeclampsia","Biomarkers in Management of PP Preeclampsia","Inclusion Criteria:\n\n* The study population will consist of pregnant people ages 18 to 45 years old undergoing delivery in setting of preeclampsia with severe features as the experimental group and control (standard of care) groups\n* Diagnosis of PreEclampsia with severe featues must be made by standard clinical guidelines based on symptoms (persistent headache not responsive to medications, persistent right upper quadrant pain not responsive to medications), laboratory values (creatinine \\>1.1mg\u002FdL or twice the participants' baseline, AST or ALT \\> twice the upper limit of normal or twice patient's blood line, platelets \\\u003C100,000), or blood pressure criteria (Systolic \\>160 mmHg or Diastolic \\>110mmHg persistent over 15 minutes such that short acting antihypertensives are required, or Systolic \\>160mmHg or Diastolic\\>110mmHg present 4 hours or more apart)\n\nExclusion Criteria:\n\n* Exclusion criteria included Hemolysis Elevated Liver enzymes Low Platelets (HELLP) Syndrome, pulmonary edema, chronic or acute kidney injury, eclampsia, worsening neurologic symptoms, medical contraindication to magnesium (ex. Myasthenia Gravis)\n* Multiple gestations (twins, triplets, etc)\n* Inability to consent in English","FEMALE","18 Years","45 Years",{"count":20,"type":21},100,"ESTIMATED","INTERVENTIONAL",[24],"PHASE4","Participants are recruited for a research study about how lab values change following delivery in people with Preeclampsia with Severe Features. Preeclampsia with Severe Features means that the disease has impacted organs, causing high blood pressures, symptoms, or changes in lab values. Those with Preeclampsia with Severe Features receive magnesium sulfate after delivery.\n\nThe study is intended to learn how lab values change following delivery and to investigate how quickly participants get better from preeclampsia. Participation in this research will last while admitted to the hospital. Information will be collected from the post partum visit, but there is no need for blood draw at that time. The purpose of this research is to gather information on the safety and effectiveness of a shorter administration of magnesium which is approved by the Food and Drug Administration (FDA).\n\nParticipants will be randomized into two groups, which means that it will be decided by chance if 12 hours or 24 hours of magnesium will be given after the delivery of the baby.\n\nBlood samples will be collected at time of delivery, 12 hours after delivery, 18 hours after delivery, 24 hours after delivery, and then daily. This is very similar to the number of labs to be collected even if participants decide not to participate in this study. This would likely add 2 or 3 blood draws. Both groups will have the same number of blood draws collected.\n\nOther than possibly having 12 hours of magnesium, and a few more blood draws, the rest of the care received will not change. Each blood draw will consist of \\~10mL, meaning a total of about 40mL of blood would be drawn for the purpose of this study.\n\nData would be collected, and deidentified. Information collected would include age, other medical conditions (like diabetes or high blood pressure out side of pregnancy), blood pressure, and symptoms during hospital stay and at the post partum visit.",[27,28],"Preeclampsia Severe","Preeclampsia Postpartum",[30,31,32,33],"PreEclampsia","Magnesium Sulfate","Post Partum","PreEclampsia with Severe Features","NOT_YET_RECRUITING","2026-05-27",{"date":37,"type":38},"2026-06-01","ACTUAL",{"date":40,"type":21},"2026-06",{"date":42,"type":21},"2027-08-31",{"name":44,"class":45},"Alexander Harrison","OTHER",1,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":53,"eligibilityCriteria":54,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":55,"targetDuration":4,"studyType":22,"phases":56,"briefSummary":57,"conditions":58,"keywords":64,"overallStatus":74,"whyStopped":4,"lastUpdateSubmitDate":75,"lastUpdatePostDateStruct":76,"startDateStruct":78,"completionDateStruct":80,"leadSponsor":82,"locationsCount":46},"100620750","phase-4-lda-and-lmwh-vs-lda-alone-in-high-risk-patients-for-preeclampsia-prevention-100620750","NCT07361679","LDA and LMWH vs LDA Alone in High-risk Patients for Preeclampsia Prevention","Combined Administration of Low Molecular Weight Heparin and Aspirin Versus Aspirin Alone in Gravidas at High Risk for Preeclampsia: A Randomized Controlled Trial","preGO","Inclusion Criteria:\n\n* Singleton pregnancy\n* High risk for preeclampsia (risk \\>1:150) based on FMF screening algorithm combining first-trimester ultrasound, biochemical markers, and medical history\n* Gestational age \\\u003C16 weeks at enrollment\n* Maternal age ≥18 years\n* Willing and able to provide written informed consent\n* Adequate ability for follow-up (direct telephone communication, accessible residence)\n\nExclusion Criteria:\n\n* Multiple pregnancy\n* Current permanent aspirin use for other medical indications\n* Serious congenital fetal abnormality detected on ultrasound\n* Contraindication to aspirin or low molecular weight heparin including: known hypersensitivity, active peptic ulcer disease, bleeding disorders or coagulopathy, severe thrombocytopenia (platelet count \\\u003C100,000\u002FμL), active or recent significant bleeding, history of heparin-induced thrombocytopenia\n* Pre-existing severe renal failure (creatinine clearance \\\u003C30 mL\u002Fmin)\n* Unable to provide informed consent\n* Low probability of adequate follow-up (residence in remote areas without telephone access, accommodation in temporary structures)",{"count":20,"type":21},[24],"Preeclampsia is a major cause of maternal and perinatal morbidity and mortality worldwide. Low-dose aspirin started in the first trimester reduces the risk of preeclampsia in high-risk women. Low molecular weight heparin (LMWH) has shown potential benefits in addition to aspirin for preventing preeclampsia through its anticoagulant, anti-inflammatory, and endothelial protective effects. However, current evidence is limited and conflicting regarding the added value of LMWH to aspirin. This randomized controlled trial aims to evaluate the efficacy of combined aspirin and LMWH, compared to aspirin alone, for reducing the incidence of preeclampsia in high-risk gravidas.",[27,59,60,61,62,63],"Toxemia Of Pregnancy","Preeclampsia","Pregnancy Complications","Hypertension, Pregnancy-Induced","Gestational Hypertension",[65,66,67,68,69,70,71,72,73],"preeclampsia","gestational hypertension","toxemia","Preeclampsia prevention","Low molecular weight heparin","tinzaparin","High-risk pregnancy","LMWH","Maternal-fetal medicine","RECRUITING","2026-01-15",{"date":77,"type":38},"2026-01-23",{"date":79,"type":38},"2023-01-18",{"date":81,"type":21},"2027-07-01",{"name":83,"class":45},"Alexandra Hospital, Athens, Greece"]